- OncoGenex Pharmaceuticals (OGXI) jumps 10% before the bell.
- Needham's Chad Messer says that "while Xtandi and other prostate cancer agents in development may eventually erode chemotherapy use in prostate cancer, this concern is nothing new and [may not] have a material effect on the long-term value" of the shares.
- OGXI upgraded to Strong Buy. Price target lifted to $30 (from $20) — so Messer is essentially looking for the shares to quadruple.
OncoGenex gets a lift from Needham
Oct 28 2013, 08:48 ET